Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
The chart shows the growth of an initial investment of $10,000 in Merit Medical Systems Inc, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Merit Medical Systems Inc (MMSI) has returned -22.81% so far this year and -24.78% over the past 12 months. Looking at the last ten years, MMSI has achieved an annualized return of 13.73%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
MMSI
1M-7.99%
6M-19.20%
YTD-22.81%
1Y-24.78%
5Y1.84%
10Y13.73%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Merit Medical Systems Inc (MMSI) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-7.55%
-4.89%
-9.74%
-2.52%
2025
12.29%
-5.52%
3.69%
-10.35%
0.61%
-1.09%
-8.76%
8.07%
-7.44%
6.48%
-0.47%
1.91%
2024
3.71%
-3.02%
-1.26%
-2.41%
8.69%
5.05%
-0.51%
14.00%
3.86%
0.25%
5.32%
-6.72%
2023
0.46%
-0.79%
5.15%
10.19%
1.52%
1.85%
-10.45%
-12.03%
5.17%
-0.01%
4.10%
6.24%
2022
-11.01%
16.88%
2.26%
-7.14%
-1.18%
-11.90%
6.54%
4.39%
-3.25%
20.46%
3.91%
-1.92%
2021
-2.63%
2.41%
6.23%
6.11%
-5.30%
6.86%
8.38%
1.74%
0.03%
-6.52%
-6.69%
-1.64%
2020
15.95%
-6.44%
-14.05%
35.70%
12.87%
0.71%
-1.91%
9.04%
-11.82%
14.11%
9.81%
0.51%
2019
3.01%
-1.05%
11.35%
-10.10%
-8.29%
14.54%
-34.23%
-13.18%
-11.89%
-31.94%
34.55%
11.90%
2018
8.15%
-1.30%
-2.26%
8.26%
5.88%
1.69%
5.33%
8.38%
4.33%
-7.03%
9.73%
-12.84%
2017
-4.15%
20.31%
-7.67%
16.61%
4.41%
7.31%
7.19%
-0.36%
2.42%
-10.58%
13.89%
-0.69%
2016
9.93%
-7.76%
6.27%
18.20%
4.08%
-9.07%
7.53%
12.29%
Performance Indicators
The charts below present risk-adjusted performance metrics for Merit Medical Systems Inc (MMSI) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MMSI compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Merit Medical Systems Inc volatility is 1.57%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Liabilities And Equity (USD)
2.69B
2.42B
2.33B
1.66B
1.65B
1.66B
1.76B
1.62B
1.11B
942.80M
778.73M
747.17M
728.28M
705.31M
447.02M
Equity Attributable To Parent (USD)
1.58B
1.38B
1.20B
1.14B
1.04B
958.58M
949.94M
932.78M
676.33M
498.19M
466.10M
435.26M
405.71M
381.58M
357.09M
Equity Attributable To Noncontrolling Interest (USD)
Merit Medical Systems has acquired View Point Medical, Inc. for approximately $140 million ($90 million cash at closing plus $25 million deferred payments over two years). View Point manufactures the OneMark Detection Imaging System for breast and soft tissue tumor localization. The acquisition is expected to be dilutive to Merit's 2026 earnings but accretive in 2027 and beyond, with projected revenue contribution of $2-4 million in 2026 and $14-16 million in 2027.
Benzinga•
AI Insight
The acquisition expands Merit's therapeutic oncology portfolio and leadership position in breast localization procedures. While dilutive to 2026 earnings, the deal is projected to be accretive in 2027 and beyond with strong revenue growth (20%+ annually) and 70% non-GAAP gross margins, representing strategic value creation.
The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.
GlobeNewswire Inc.•Sns Insider Research
AI Insight
Listed as a key market player but no specific recent developments or product announcements mentioned in the article.
Merit, a global engagement and incentives technology company headquartered in Riyadh, has acquired Synchro Marketing, an Australian leader in sales incentive programs for automotive and oil & gas sectors. The acquisition accelerates Merit's global expansion and enhances its sector-specific capabilities, particularly in the APAC region. Synchro will continue operating under current leadership while integrating into Merit's global platform.
Benzinga•Globe Newswire
AI Insight
Strategic acquisition strengthens Merit's global platform, expands APAC presence, and enhances capabilities in high-demand sectors. The company demonstrates growth momentum with recent Series B funding of $40 million and successful integration of established market leader Synchro.
Merit Medical Systems has signed an asset purchase agreement with PENTAX Medical to acquire the C2 CryoBalloon device for $22 million, expanding its endoscopy portfolio in the gastroenterology market with technology to treat Barrett's esophagus and other gastrointestinal disorders.
Benzinga•Globe Newswire
AI Insight
Expanding product portfolio, acquiring innovative medical technology, projecting revenue growth and strategic market positioning
Merit Medicine has integrated Willis Towers Watson's HealthMAPS® manuals into its Merit Predict predictive analytics solution, enabling more precise group health risk assessment by combining actuarial expertise with advanced predictive modeling.
GlobeNewswire Inc.•Ali Panjwani
AI Insight
Expanding capabilities by integrating advanced actuarial tools, demonstrating innovation and strategic growth
Merit Medical received CE Mark approval for Embosphere Microspheres to treat knee osteoarthritis through genicular artery embolisation, offering a minimally invasive pain management option with proven clinical success.
GlobeNewswire Inc.•Merit Medical Systems, Inc.
AI Insight
Achieved CE Mark for innovative medical treatment, expanded product indication, demonstrated clinical effectiveness, and positioned as a leader in minimally invasive therapies
Merit Medical Systems reported strong Q2 2025 financial results, with revenue of $382.5 million (up 13.2%), beating analyst estimates. The company showed robust growth in cardiovascular and endoscopy device segments and raised its full-year guidance.
The Motley Fool•Jesterai
AI Insight
Exceeded analyst expectations, reported revenue growth of 13.2%, improved non-GAAP gross and operating margins, raised full-year guidance, and showed strong performance across product segments, particularly in Cardiac Intervention and Endoscopy
The global blood pressure monitor market is projected to grow from USD 2.40 billion in 2025 to USD 4.36 billion by 2035, driven by aging populations, home healthcare, and AI-powered wearables. The rising prevalence of hypertension and technological advancements are key factors driving the market growth.
GlobeNewswire Inc.•Future Market Insights, Inc.
AI Insight
Merit Medical Systems is listed as one of the key companies in the blood pressure monitor market, indicating their importance and potential to benefit from the market growth.
Merit Medical Systems announced the resignation of its President, Joseph C. Wright, effective January 3, 2025, following an investigation into allegations regarding his conduct. The company's Board of Directors has re-appointed Fred P. Lampropoulos as the new President.
GlobeNewswire Inc.•
AI Insight
The article presents a neutral tone, as it simply reports on the resignation of the company's president and the appointment of a new one, without any clear indication of positive or negative implications for the company's operations or performance.
The global guidewires market is expected to grow from $4.15 billion in 2024 to $6.89 billion by 2034, driven by increased demand for minimally invasive procedures and technological advancements in guidewire materials and design.
GlobeNewswire Inc.•Sabyasachi Ghosh
AI Insight
The article mentions Merit Medical Inc. as a key player in the guidewires industry, indicating their strong presence and potential to benefit from the market growth.
